News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
544,190 Results
Type
Article (39706)
Company Profile (72)
Press Release (504412)
Multimedia
Podcasts (44)
Webinars (11)
Section
Business (151673)
Career Advice (2429)
Deals (27670)
Drug Delivery (98)
Drug Development (72778)
Employer Resources (141)
FDA (13591)
Job Trends (12195)
News (270814)
Policy (26934)
Tag
Academia (2532)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (78)
Alliances (38302)
ALS (90)
Alzheimer's disease (1391)
Antibody-drug conjugate (ADC) (127)
Approvals (13587)
Artificial intelligence (237)
Autoimmune disease (22)
Automation (16)
Bankruptcy (309)
Best Places to Work (9994)
BIOSECURE Act (15)
Biosimilars (90)
Biotechnology (59)
Bladder cancer (80)
Brain cancer (26)
Breast cancer (264)
Cancer (2140)
Cardiovascular disease (184)
Career advice (2041)
Career pathing (32)
CAR-T (143)
Cell therapy (394)
Cervical cancer (16)
Clinical research (59417)
Collaboration (705)
Company closure (1)
Compensation (276)
Complete response letters (22)
COVID-19 (2462)
CRISPR (39)
C-suite (251)
Cystic fibrosis (83)
Data (2118)
Decentralized trials (2)
Denatured (6)
Depression (51)
Diabetes (255)
Diagnostics (5706)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (111)
Drug pricing (93)
Drug shortages (23)
Duchenne muscular dystrophy (89)
Earnings (54740)
Editorial (38)
Employer branding (18)
Employer resources (128)
Events (74642)
Executive appointments (717)
FDA (14738)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (656)
Gene editing (98)
Generative AI (19)
Gene therapy (299)
GLP-1 (691)
Government (4124)
Grass and pollen (5)
Guidances (64)
Healthcare (15995)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (126)
Indications (27)
Infectious disease (2604)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (50)
Intellectual property (88)
Interviews (522)
IPO (12509)
IRA (41)
Job creations (2580)
Job search strategy (1670)
Kidney cancer (11)
Labor market (19)
Layoffs (420)
Leadership (23)
Legal (5738)
Liver cancer (72)
Lung cancer (319)
Lymphoma (144)
Machine learning (6)
Management (51)
Manufacturing (253)
MASH (74)
Medical device (10583)
Medtech (10587)
Mergers & acquisitions (15640)
Metabolic disorders (663)
Multiple sclerosis (77)
NASH (23)
Neurodegenerative disease (99)
Neuropsychiatric disorders (31)
Neuroscience (1935)
NextGen: Class of 2025 (5527)
Non-profit (3975)
Now hiring (31)
Obesity (342)
Opinion (210)
Ovarian cancer (72)
Pain (86)
Pancreatic cancer (80)
Parkinson's disease (145)
Partnered (17)
Patents (217)
Patient recruitment (106)
Peanut (41)
People (50800)
Pharmaceutical (22)
Pharmacy benefit managers (10)
Phase I (18283)
Phase II (26124)
Phase III (19963)
Pipeline (1155)
Policy (132)
Postmarket research (2311)
Preclinical (7470)
Press Release (54)
Prostate cancer (99)
Psychedelics (37)
Radiopharmaceuticals (214)
Rare diseases (360)
Real estate (4091)
Recruiting (56)
Regulatory (19061)
Reports (25)
Research institute (2115)
Resumes & cover letters (356)
Rett syndrome (5)
RNA editing (3)
RSV (39)
Schizophrenia (75)
Series A (116)
Series B (74)
Service/supplier (3)
Sickle cell disease (52)
Special edition (10)
Spinal muscular atrophy (145)
Sponsored (28)
Startups (2729)
State (2)
Stomach cancer (14)
Supply chain (57)
Tariffs (31)
The Weekly (37)
Vaccines (636)
Venture capitalists (31)
Weight loss (230)
Women's health (25)
Worklife (17)
Date
Today (27)
Last 7 days (757)
Last 30 days (2199)
Last 365 days (28334)
2025 (9307)
2024 (30550)
2023 (34094)
2022 (44521)
2021 (47764)
2020 (46280)
2019 (39628)
2018 (30032)
2017 (26941)
2016 (25609)
2015 (29974)
2014 (22438)
2013 (18236)
2012 (19470)
2011 (20494)
2010 (18089)
Location
Africa (719)
Alabama (48)
Alaska (4)
Arizona (143)
Arkansas (11)
Asia (33571)
Australia (7019)
California (5042)
Canada (1806)
China (467)
Colorado (225)
Connecticut (216)
Delaware (132)
Europe (75028)
Florida (805)
Georgia (168)
Idaho (48)
Illinois (461)
India (23)
Indiana (268)
Iowa (7)
Japan (151)
Kansas (88)
Kentucky (19)
Louisiana (8)
Maine (49)
Maryland (779)
Massachusetts (3597)
Michigan (193)
Minnesota (291)
Mississippi (1)
Missouri (75)
Montana (21)
Nebraska (22)
Nevada (56)
New Hampshire (63)
New Jersey (1507)
New Mexico (20)
New York (1481)
North Carolina (788)
North Dakota (5)
Northern California (2193)
Ohio (164)
Oklahoma (5)
Oregon (25)
Pennsylvania (1141)
Puerto Rico (12)
Rhode Island (27)
South America (987)
South Carolina (19)
South Dakota (1)
Southern California (1956)
Tennessee (81)
Texas (772)
United States (19122)
Utah (166)
Virginia (132)
Washington D.C. (50)
Washington State (471)
West Virginia (3)
Wisconsin (42)
544,190 Results for "bioohio formerly known as omeris".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Press Releases
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
January 7, 2025
·
1 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Press Releases
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 3, 2025
·
5 min read
Press Releases
1Cell.Ai, Formerly OneCell Diagnostics, Launches OncoIncytes Integrating Multi-Modal Data for Precision Oncology
April 23, 2025
·
3 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Venture capitalists
Bausch Health Tussles With Activist Investor Carl Icahn After Popping Poison Pill
Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity from taking control of the company to the detriment of other shareholders.
April 23, 2025
·
1 min read
·
Tristan Manalac
1 of 54,419
Next
